Background and Purpose-Secondary stroke prevention treatments vary in different regions of the US. We determined the degree to which guideline-recommended stroke treatments vary by region for patients treated at hospitals participating in a voluntary national quality improvement program, Get With The Guidelines-Stroke. Methods-Receipt of 8 guideline-recommended treatments (intravenous tissue-type plasminogen activator, antihypertensives, antithrombotics, anticoagulants for atrial fibrillation, deep vein thrombosis prophylaxis, lipid-lowering medications at discharge, smoking cessation counseling, weight loss education) and defect-free care were compared in 4 US regions among eligible patients with ischemic stroke and transient ischemic attack; there was adjustment for patient demographics, medical history, and hospital characteristics. 
T here are regional differences in the rates of recurrent stroke in the United States. 1, 2 Although several factors may contribute to these disparities, at least some of the variation may be caused by well-described geographic differences in stroke-related healthcare utilization. Such variation is present among both Veterans Administration patients 3 and Medicare beneficiaries 4 ; this includes regional differences in the use of intravenous tissue plasminogen activator (IV-tPA) for patients with acute ischemic stroke 5 and less frequent use of antithrombotics at discharge and warfarin for atrial fibrillation in the Southeast. 4 Several registries and programs to assess and improve the quality of stroke patient care and outcomes have been developed, which if effectively implemented, might reduce differences in the use of evidence-based treatments and interventions. 6, 7 We hypothesized that regional differences in the use of recommended stroke-related therapies (IVtPA, those aimed at limiting complications and secondary prevention interventions) would not be present in patients cared for in hospitals participating in a national US voluntary quality improvement program, Get With the Guidelines-Stroke (GWTG-Stroke).
Methods
The methods of the GWTG-Stroke program have been described previously. 8 -10 Briefly, all GWTG-Stroke data are collected using the Internet-based Patient Management Tool (Outcome Sciences, Inc), in which data are coded, deidentified, and securely transmitted. Patient demographics, medical history, initial brain computed tomography findings, in-hospital treatments and events, discharge treatments, counseling, and discharge destination were collected for each hospitalization.
Hospital characteristics were obtained from the American Hospital Association database and included academic or nonacademic status, annual volume of stroke discharges, and geographical region. Each participating institution received human research approval or an exemption from their institutional review board to record patient data for GWTG-Stroke without individual patient consent. Institutional review boards at the majority of institutions determined the study was exempt. Joint Commission Primary Stroke Center (JC-PSC) certification was determined using the Joint Commission's publicly available list. 
Measures
Eight evidence-based quality measures were used to compare the quality of care by geographic region. These included (1) the rate of use of IV-tPA in patients with ischemic stroke without contraindications who presented to the emergency department within 2 hours and were treated within 3 hours of symptom onset. Measures reflecting the use of secondary prevention treatments at discharge included: (2) antithrombotic medications (antithrombotics), including platelet antiaggregants (aspirin, aspirin/dipyridamole, ticlopidine, clopidogrel) and anticoagulants (heparin and warfarin); (3) anticoagulation (ie, warfarin, full-dose heparin, or other anticoagulants) for atrial fibrillation (paroxysmal or chronic; anticoagulants); (4) deep vein thrombolysis (DVT) prophylaxis by second day; (5) lipid-lowering agents for patients with low-density lipoprotein cholesterol Ͼ100 mg/dL, those on lipid-lowering agents before admission, or those in whom low-density lipoprotein was not measured in the past 30 days (lipid-lowering therapy); (6) antihypertensives at or before discharge (antihypertensives) in patients without contraindications; (7) smoking cessation counseling or medication provided at or before discharge for current smokers (any cigarettes in past year; smoking cessation); and (8) weight loss education for patients with a body mass indexՆ30 (weight loss education). We also examined the receipt of defect-free care as an aggregate measure of overall quality of care, consistent with the approach developed within GWTG-Stroke. 9, 10 A patient received defect-free care if they received all interventions for which they were eligible. Patients with documented valid reasons for nontreatment were excluded from the denominator for the measures. 8 
Statistical Analysis
Chi-square tests were used to evaluate the significance of differences for categorical variables, and Wilcoxon or Kruskal-Wallis tests were used for continuous variables. Logistic regression analyses using generalized estimating equations to account for clustering by hospital were used to adjust for patient demographics (age, sex, race/ ethnicity), medical history (atrial fibrillation/flutter, previous stroke or TIA, peripheral vascular disease or previous acute myocardial infarction, carotid stenosis, diabetes, hypertension, dyslipidemia, peripheral vascular disease), and hospital characteristics (teaching hospital, annual stroke discharge rate, length of time in GWTGStroke 8 ). Risk-adjusted analyses for the use of IV-tPA and defectfree care also included JC-PSC certification status. Global probability values were calculated for region. In addition, statistical differences were examined for each region using the Northeast as the referent region. To determine whether regional differences varied by race/ethnicity or length of time in GWTG-Stroke, a race-by-region and length-of-time-in-GWTG-Stroke-by-region interaction term was included in both unadjusted and adjusted regression analyses. In sensitivity analyses, models were stratified by ischemic stroke and TIA diagnoses. Statistical analyses were performed using SAS version 9.2.
Results
A total of 1 379 034 patients were admitted to 1620 GWTGStroke-participating hospitals during the study period. Individuals were excluded from the analyses if they experienced a stroke type other than ischemic or TIA (14.2%), were admitted to sites with Ͻ75% completeness of medical history items (0.9% from across 40 sites), were documented to only receive comfort care (2%), had a stroke that occurred during hospitalization for another condition (0.9%), or had missing/ undetermined race (2.7%). For all measures except acute treatments of IV-tPA, individuals were excluded if they left against medical advice (0.1%), discontinued care, or died in-hospital (7.4%) The number of patients excluded based on these criteria varied by region. The percentage of patients meeting inclusion criteria ranged from 67.3% to 75.5% across regions. The final sample included 991 995 patients from 1564 hospitals; the mean age was 70.3 years, 53% were women, 80% were white, and 15% were black. More than two thirds had an acute ischemic stroke. Over 37% of the admissions were from the South, 27.6% from the Northeast, 19.3% from the Midwest, and 15.9% from the West. Patient characteristics, hospital bed capacity, and the percentage of academic hospitals varied by region (Table 1) . Overall, 11% of patients were treated at a JC-PSC-certified site. The percentage of patients eligible for each outcome varied by region (Table 2) . Overall, 4.7% were eligible for TPA, 94.1% for antithrombotics, 12.7% for anticoagulants, 33.6% for DVT prophylaxis, 91.0% for antihypertensive medications, 61.0% for lipid-lowering medications, 16.5% for smoking cessation education, 22.1% for weight loss counseling, and 98.1% for the calculation of defect-free care.
Among eligible patients, 62.7% received IV-tPA, 81.5% antihypertensives, 96.3% antithrombotics; 91.4% of those with atrial fibrillation received anticoagulants, 89.7% received DVT prophylaxis, 73.7% lipid-lowering therapy, 91.7% smoking education, and 52.5% weight loss education; and 73.9% received defect-free care. In unadjusted analyses, the receipt of each of these measures varied by region (Figure 1) , particularly the receipt of IV-tPA, for which rates were lowest in the South (58.8%) and Midwest (58.2%) compared with those in the Northeast (67.8%) and West (67.8%).
In risk-adjusted analyses, there were regional differences in the use of IV-tPA (global probability value, Ͻ0.01), antihypertensive medications (Pϭ0.02), antithrombotics (Pϭ0.04), lipid-lowering medications (PϽ0.01), DVT prophylaxis (Pϭ0.02), weight loss counseling (Pϭ0.03), and the receipt of defect-free care (PϽ0.01). Overall, regional differences were not significant for the use of anticoagulants for atrial fibrillation (Pϭ0.18) or smoking cessation education (Pϭ0.3). When each region was compared separately using the Northeast as the reference group (Figure 2 
1.53])
. Similar patterns were found in analyses stratified by acute ischemic stroke and TIA diagnoses. Race/ethnicityby-region interaction terms were not significant for any of the quality measures in either adjusted or unadjusted analyses. For defect-free care, the time-in-GWTG-Strokeand-region interaction term was significant (PϽ0.001), predominantly because of lower odds in hospitals in the Midwest compared with the Northeast after being in the program more than 2 years. The reason for this difference is unclear.
Discussion
Previous work shows that the GWTG-Stroke program is associated with sustained improvements in the quality of stroke care. 8 We found that the rates of use of recommended treatments among eligible patients in GWTG-Stroke hospitals The percent eligible for each outcome was significantly different by region, PϽ0.001. 
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were at the high end of ranges reported from those in other US studies. These studies reflect rates of IV-tPA use among eligible patients in the US ranging from 37% to 43%, [11] [12] [13] antihypertensive medications at discharge from 69% to 89%, 14 -16 DVT prophylaxis from 14% to 43%, [17] [18] [19] lipidlowering medications from 65% to 78%, 14, 15 anticoagulants from 83%, 12, 18 antithrombotics from 83% to 97%, 4, 12, 15, 18 and smoking cessation counseling from 79%. 12 Relatively little is known about the prevalence of weight loss counseling among stroke and TIA survivors. Overall compliance rates with recommended therapies were high; however, we found persistent regional differences in the receipt of several individual measures: these included the receipt of IV tPA, lipid-lowering medications, and antihypertensive medications, as well as a measure of defect-free care among eligible patients, despite participation in a program aimed at promoting uniform, high-quality care. In general, receipt rates tended to be lower in the Midwest and South compared with the Northeast, even after risk adjustment for patient and hospital characteristics. Improvements in stroke care, particularly in the South and Midwest regions, where recurrent stroke hospitalizations have been shown to be higher, 1,2 could reduce the future burden of stroke morbidity and mortality.
Previous studies have documented regional differences in stroke care. A national study of Medicare fee-for-service beneficiaries found differences in state-specific rates of warfarin use for atrial fibrillation, avoidance of sublingual nifedipine, and antithrombotic medications prescribed at discharge. 4 Although the comparisons were not adjusted for patient or hospital characteristics, more populous states and those in the Southeast had consistently poorer performance. 4 Regional differences in the rates of use of IV-tPA among all ischemic stroke patients were also found for Medicare beneficiaries, with overall treatment rates highest among hospitals in the Northeast (2.7%) and lowest among hospitals in the South (1.8%) and Midwest (2.0%). 5 The Paul Coverdell National Acute Stroke Registry found that quality of stroke care summarized as a composite of 8 performance measures varied by state in unadjusted, but not in risk-adjusted, analyses. 20 The reasons for these regional differences in GWTGStroke hospitals and other registries and programs remain unclear. Previous studies suggest that regional patterns of care, particularly for treatments such as IV-tPA, for which relatively few stroke patients are eligible, may reflect differences in hospital characteristics, such as bed capacity or teaching status; yet, we found that differences persisted after adjustment for these characteristics. Because Joint Commission Primary Stroke Center certification is associated with an increase in the utilization of IV-tPA, 21 and the percentage of hospitals with JC-PSCs varies by region across the country, 22 we adjusted for JC-PSC status; however, this did not alter the results. In addition, an analysis of GWTG-Stroke data found that black patients with stroke receive fewer recommended treatments com- pared with Hispanic/Latino or white patients. 10 Because there is a higher proportion of black persons in the South, we explored whether regional patterns of care were related to race/ethnicity. Blacks were less likely to receive many of the recommended stroke treatments in all regions of the US, but this did not account for the lower rates of receipt in the South and Midwest. Because the analysis was regionally based, the differences cannot be ascribed to variations in state-based regulations or care delivery systems.
This study has several limitations. The data reflect patients treated at GWTG-Stroke hospitals; hence, the results may not be generalizable to other settings. Several of the recommended treatments have been associated with hospital performance awards since 2003, whereas some have been recently added as quality measures in the program. Although it is unlikely, this may have led to differential data collection of the selected measures. The rates of utilization and finding of regional care differences, however, are consistent with previous reports. We were unable to adjust for insurance status because rates of missing data were too high. In addition, duration of participation in GWTG has been associated with improved performance. 8 There was, however, regional heterogeneity based on duration of participation for hospitals in the Midwest compared with in the Northeast. The reasons for this observation are not clear. Although our study used explicit criteria to identify patients eligible for treatment, categorization is dependent on the accuracy of recorded information, and it may not account for all patient or hospital information that could influence treatment decisions. However, we were able to show that regional differences persisted despite adjustment for patient age, race, and medical comorbidities; annual volume of stroke discharges; hospital academic teaching status; length of time the hospital participated in GWTGStroke; and in the analyses of tPA use, Joint Commission primary stroke center status. This study examined the use of medications in-hospital and at discharge. We do not have data reflecting out-of hospital usage. The AVAIL study (a GWTG-stroke substudy) found that patients tend to persist with discharge medications unless advised to change by a healthcare provider. 14, 23 We were unable to compare differences at a state level because of data use restrictions. The large sample size increased the likelihood that even small differences would be statistically significant; however, we tested an a priori hypothesis and focused on clinically meaningful differences.
Despite generally high rates of 8 recommended evidencebased treatments in GWTG-Stroke hospitals, regional differences remain, including the use of IV-tPA , lipid-lowering medications, and antihypertensive medications, as well as an aggregate measure of overall quality of care; this exists even after adjustment for patient and hospital characteristics. The reasons for these regional differences in the utilization of guideline-based stroke treatments among hospitals voluntarily participating in a national stroke quality improvement program warrants additional investigation to identify strategies to reduce variation of care.
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